LGR5 is involved in promoting tumor progression via EMT and WNT/β-catenin pathways and increased LGR5 expression is associated with chemotherapy resistance and recurrence in different cancers including breast, cervical, CRC, gastric, HCC and ovarian carcinoma. The gene discussed is LGR5; the disease is hepatocellular carcinoma.